Accession Number ADA570122
Title Development of a Novel Synthetic Drug for Osteoporosis and Fracture Healing.
Publication Date Sep 2012
Media Count 21p
Personal Author H. Yokota
Abstract This is a progress report (year 1) for developing a novel therapeutic drug for skeletal diseases, in particular focusing on administration of salubrinal for treatment of osteoporosis and bone fracture. A formulation for salubrinal was determined and an effective dosage was identified. Using ovariectomized mice, administration of salubrinal was shown to reduce body weight and fat weight, and to prevent reduction in uterus weight and BMD/BMC. Salubrinal was also shown to inhibit osteoclast development and to stimulate osteoblast development through regulation of key transcription factors such as ATF4, NF B, and NFATc1. A pathway analysis revealed that the observed effects of salubrinal were mediated by eIF2, p38 MAPK, and NF B pathways. Multiple invention disclosures and patents were submitted or being prepared for bone remodeling, fat metabolism, joint preservation, cancer treatment, and salubrinal coating on transplantable materials. A collaborative relationship was established with Zimmer Co. Two research abstracts were submitted, two peer-reviewed articles are in press, and one peer-reviewed research article was submitted.
Keywords Bone fractures
Cancer
Healing
Lipid metabolism
Osteoporosis
Skeleton
Therapy
Uterus


 
Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Indiana Univ. at Indianapolis.
Document Type Technical report
Title Note Annual rept. 22 Aug 2011-21 Aug 2012.
NTIS Issue Number 1314
Contract Number W81XWH-11-1-0716

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader